Core Viewpoint - NorthStrive Biosciences Inc. has initiated Phase III of its AI Development Program in collaboration with Yuva Biosciences, marking a significant advancement in developing therapies for obesity and related metabolic conditions [1][2]. Group 1: Phase III Development - Phase III aims to build on Phase II results, where YuvaBio utilized its MitoNova™ AI platform to identify small-molecule candidates that promote mitochondrial health and muscle preservation, particularly relevant for patients using GLP-1 receptor agonists [2][7]. - The Phase III program will generate biological data on AI-selected compounds, including cytotoxicity screening and ANT1 expression testing, and is expected to last approximately 6 to 9 weeks [2][7]. Group 2: Company Background - Yuva Biosciences, Inc. focuses on leveraging mitochondrial science and AI to develop therapeutic candidates targeting aging-related and metabolic pathways, utilizing its proprietary MitoNova™ platform [3]. - NorthStrive Biosciences Inc. specializes in developing aesthetic medicines, with its lead asset, EL-22, designed to address muscle preservation during weight loss treatments [4]. - PMGC Holdings Inc. is a diversified holding company managing a portfolio of subsidiaries, including NorthStrive Biosciences, and is committed to exploring growth opportunities across various sectors [5].

Core Insights - Northstrive Biosciences Inc. has completed Phase II of its AI Development Program in collaboration with Yuva Biosciences, focusing on small molecule candidates to promote mitochondrial health for combating obesity and cardiac diseases [1][6] Company Overview - Northstrive Biosciences Inc. is a biopharmaceutical company under PMGC Holdings Inc., specializing in the development of aesthetic medicines, with its lead asset EL-22 aimed at preserving muscle during weight loss treatments [3] - PMGC Holdings Inc. is a diversified holding company that manages a portfolio through strategic acquisitions and investments across various industries [4] Collaboration Details - YuvaBio completed Phase II by compiling a targeted collection of compounds from 12 curated libraries, focusing on obesity, cardiometabolic disorders, and lipid & glucose metabolism [2] - The MitoNova™ AI platform was utilized to screen compounds for their potential impact on muscle preservation and metabolic health, resulting in a shortlist of candidates for biological validation [2][6]